CXCR2 inhibition: a novel approach to treating coronary heart disease
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 11 Sep 2017
At a glance
- Drugs AZD 5069 (Primary)
- Indications Coronary disorders
- Focus Therapeutic Use
- 09 Sep 2017 Planned number of patients changed from 90 to 102.
- 03 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 02 Mar 2016 New trial record